Announcements Trials
Browse Landscape

Phase

Phase 3 11Phase 2 10Phase NA 9Phase 4 3Phase 1 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Tumor-Agnostic 1Plasma cell 1

Conditions

Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × Ondansetron × Clear all
NCT03030417 2024-12-10

Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled 35 charts
Lymphoid

Lymphoma

NCT02648490 2019-07-30

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers

Henlix, Inc

Phase 1 Completed
19 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT00871910 2017-10-23

Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)

Merck Sharp & Dohme LLC

Phase 1 Completed
81 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡